<DOC>
	<DOCNO>NCT00115076</DOCNO>
	<brief_summary>Our laboratory study skin disease know psoriasis . The purpose protocol study action effect Efalizumab , psoriasis . This medication study extensively find effective safe treatment psoriasis . The eligible patient 10 % his/her body surface area involve psoriasis vulgaris .</brief_summary>
	<brief_title>Study Drug Efalizumab ( Raptiva ) , Adult Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>The eligible patient receive drug Efalizumab , weekly 12 week , injection . The patient see weekly 12 week every week 12 week follow . At visit , patient expect physical skin exam do . At specific week , blood work drawn , clinical photography take skin biopsy do . Two type skin biopsy do local anesthesia administer . One punch biopsy small piece skin take , approximate size pencil eraser . The second type skin biopsy shave biopsy , postage size piece skin take .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed informed consent Plaque psoriasis cover &gt; 10 % total BSA Diagnosis plaque psoriasis least 6 month PASI score &gt; =12 ( see Appendix A ) Linear PASI score &gt; = 8.0 screening ( see Appendix B ) In opinion investigator , candidate systemic therapy psoriasis : Who previously treat ( naive systemic treatment ) OR Who prior treatment systemic therapy psoriasis ( e.g. , PUVA , cyclosporine , corticosteroid , methotrexate , oral retinoids , mycophenolate mofetil ( MMF ) , thioguanine , hydroxyurea , sirolimus , azathioprine , 6MP , etanercept ) Body weight &lt; 140 kg 18 75 year old . As risk Efalizumab childhood unknown , &lt; 18years exclude study For woman childbearing potential men whose partner may become pregnant , willingness use acceptable method contraception prevent pregnancy duration study ( receive study medication 3 month follow ) . Acceptable method contraception include use condom ; abstinence ; use sexual partner oral implantable injectable contraceptive , IUD , female condom , diaphragm spermicide , cervical cap ; sterile sexual partner Willingness hold sun exposure reasonably constant avoid use tan booth UV light source study Exclusion Criteria Subjects meet follow exclusion criterion ineligible study entry : Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis History severe allergic anaphylactic reaction humanize monoclonal antibody fusion protein contain Ig Fc region Clinically significant psoriasis flare screen first treatment day Treatment efalizumab ( antiCD11a ) within last 12 month enrollment Pregnancy lactation . As risk Efalizumab pregnancy unknown , pregnant woman exclude study History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History active tuberculosis ( TB ) currently undergo treatment TB . PPD test chest Xray require highrisk subject ( see Appendix D ) . Subjects positive PPD ( due BCG vaccination ) chest Xray exclude History opportunistic infection ( e.g. , systemic fungal infection , parasite ) Seropositivity human immunodeficiency virus ( HIV ) Seropositivity hepatitis B C virus Hepatic enzymes &gt; 3 time upper limit normal ( ULN ) Diagnosis hepatic cirrhosis , regardless cause severity WBC count &lt; 4000μL &gt; 14,000/μL Serum creatinine &gt; 2 time ULN Hospital admission cardiac disease , stroke , pulmonary disease within last year Presence malignancy within past 5 year , include lymphoproliferative disorder . Subjects history fully resolve basal cell squamous cell skin cancer may enrol History substance abuse within last 5 year Any medical condition , judgment investigator , would jeopardize subject 's safety follow exposure study drug Note : Certain medication vaccine may use specify period time prior enrollment time treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>skin</keyword>
	<keyword>psoriasis</keyword>
</DOC>